Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBST Tecentriq Hybreza Policy Update | OpenPayer
    Ask Trek AI about this page
    DraftBlueCross BlueShield of TennesseePolicy ID_CHS_66652026_1026

    Atezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza) Coverage Criteria

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_66652026_1026 alerts

    Get alerted when Policy ID_CHS_66652026_1026 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage for Tecentriq Hybreza for FDA-approved and compendial oncology indications. It applies to members whose prescribed therapy meets the listed clinical criteria and has no applicable exclusions; plan terms or government program requirements control if they conflict with the policy.

    Policy Summary
    PayerBlueCross BlueShield of Tennessee
    PolicyAtezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza) Coverage Criteria
    Policy CodePolicy ID_CHS_66652026_1026
    Change TypeNo material change
    Effective DateDecember 31, 2026
    Next Review DateN/A
    Key ActionPrior authorization is required before review of Tecentriq Hybreza coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsStandard authorization duration
    9FDA-approved disease categories
    9Compendial-use disease categories
    PD-1/PD-L1 progressionExplicit exclusion

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    TN
    State mandate jurisdiction

    Covered Indications and Exclusions

    NSCLC recurrent, advanced, or metastatic disease

    Covered for recurrent, advanced, or metastatic NSCLC when ALL of the following are met.

    Recurrent, advanced, or metastatic NSCLC

    • Permitted treatment use: The requested medication is used as continued maintenance therapy as a single agent or with bevacizumab; as first-line or subsequent therapy in combination with chemotherapy with or without bevacizumab; or as first-line or subsequent therapy as a single agent.

    NSCLC adjuvant therapy

    Covered when ALL of the following are met.

    Adjuvant NSCLC: The member has stage IB to IIIB NSCLC that is PD-L1 positive and the requested medication is used as single-agent adjuvant therapy; there are no EGFR exon 19 deletions or L858R mutations or ALK, RET, or ROS1 gene fusions unless testing is not feasible because of insufficient tissue.Stage IB to IIIB; PD-L1 positive

    Small cell lung cancer

    Covered when ALL of the following are met.

    Extensive-stage SCLC regimen: The member has extensive-stage small cell lung cancer and Tecentriq Hybreza is used in combination with etoposide and carboplatin, followed by maintenance therapy as a single agent or with lurbinectedin.

    Hepatocellular carcinoma

    Covered when ALL of the following are met.

    First-line HCC treatment: The member has progressive, unresectable, or metastatic hepatocellular carcinoma and Tecentriq Hybreza is used in combination with bevacizumab as first-line treatment.

    Melanoma

    Covered when ALL of the following are met.

    BRAF V600-positive melanoma: The member has BRAF V600 mutation-positive unresectable or metastatic melanoma and Tecentriq Hybreza is used in combination with cobimetinib (Cotellic) and vemurafenib (Zelboraf) for subsequent treatment.BRAF V600 mutation positive

    Alveolar soft part sarcoma

    Covered when ALL of the following are met.

    Unresectable or metastatic ASPS: The member has unresectable or metastatic alveolar soft part sarcoma and Tecentriq Hybreza is used as a single agent.

    Mesothelioma

    Covered when ALL of the following are met.

    Subsequent mesothelioma treatment: The member has subsequent-treatment peritoneal mesothelioma, pericardial mesothelioma, or tunica vaginalis testis mesothelioma and Tecentriq Hybreza is used in combination with bevacizumab.

    Cervical cancer

    Covered when either cervical cancer criterion is met.

    Cervical cancer treatment pathways

    • Small cell neuroendocrine carcinoma pathway: The member has persistent, recurrent, or metastatic small cell neuroendocrine carcinoma of the cervix and treatment uses etoposide with either cisplatin or carboplatin; maintenance may use Tecentriq Hybreza as a single agent.
    • Cervical carcinoma pathway: The member has recurrent or metastatic adenocarcinoma, adenosquamous, or squamous cell carcinoma and treatment uses bevacizumab, paclitaxel, and either cisplatin or carboplatin; maintenance may use Tecentriq Hybreza with bevacizumab.

    Mesothelioma

    Covered when the specified disease and regimen requirement are met.

    Peritoneal, pericardial, or tunica vaginalis testis mesothelioma: The member has subsequent-treatment peritoneal mesothelioma, pericardial mesothelioma, or tunica vaginalis testis mesothelioma.

    Tecentriq Hybreza must be used in combination with bevacizumab.

    Cervical cancer

    Covered when either cervical cancer criterion is met.

    • Small cell neuroendocrine carcinoma: Persistent, recurrent, or metastatic small cell neuroendocrine carcinoma of the cervix.

      Use with etoposide and either cisplatin or carboplatin; may be used as a single agent for maintenance.

    • Other recurrent or metastatic cervical carcinoma: Recurrent or metastatic adenocarcinoma, adenosquamous, or squamous cell carcinoma.

      Use with bevacizumab, paclitaxel, and either cisplatin or carboplatin; may be used with bevacizumab for maintenance.

    Colon cancer

    Covered when all criteria are met.

    Adjuvant stage III colon cancer

    • Required biomarker: The disease is confirmed to be deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) or has a POLE/POLD1 mutation with an ultra-hypermutated phenotype.TMB >50 mut/Mb

    Thymic carcinoma

    Covered for first-line or postoperative systemic therapy when the regimen requirement is met.

    Thymic carcinoma: The member is receiving first-line or postoperative systemic therapy for thymic carcinoma.

    Use in combination with carboplatin and paclitaxel, followed by single-agent maintenance.

    Chronic lymphocytic leukemia

    Covered when the leukemia and combination-treatment criteria are met.

    CLL with Richter's transformation: The member has chronic lymphocytic leukemia with Richter's transformation.

    Use in combination with venetoclax and obinutuzumab.

    Small bowel adenocarcinoma

    Covered when the biomarker and treatment-setting criteria are met.

    Small bowel adenocarcinoma biomarker and treatment setting

    • Treatment setting: The treatment is adjuvant, neoadjuvant for resectable disease, or for locally unresectable, medically inoperable, advanced, or metastatic disease.

      Adjuvant use is with FOLFOX or CAPEOX followed by single-agent maintenance; neoadjuvant use and treatment of advanced or metastatic disease are single-agent uses.

    Coverage is excluded when a member has experienced disease progression while receiving PD-1 or PD-L1 inhibitor therapy.

    Clinical Thresholds and Biomarker Values

    NSCLC high PD-L1 tumor-cell expression
    Tumor-cell thresholdPD-L1 stained ≥ 50% of tumor cells
    AbbreviationTC ≥ 50%
    UseHigh PD-L1 expression for first-line metastatic NSCLC
    NSCLC high PD-L1 immune-cell expression
    Immune-cell thresholdPD-L1 stained tumor-infiltrating immune cells covering ≥ 10% of the tumor area
    AbbreviationIC ≥ 10%
    UseHigh PD-L1 expression for first-line metastatic NSCLC

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Obtain prior authorization before coverage review. Confirm that the requested indication is an FDA-approved indication or a qualifying compendial use and that all applicable approval criteria are met.

    • Submit the required clinical and laboratory documentation with the request.
    Documentation Required

    Six-Month Authorization and Reauthorization

    Initial authorization and most reauthorizations are issued for 6 months when the applicable diagnosis-specific criteria are met. Document the requested indication, regimen, and authorization period.

    • Continuation authorization may be limited by total-treatment duration: up to 12 months for specified adjuvant therapy and up to 24 months for thymic carcinoma.

    Therapy and Policy Context

    Tecentriq Hybreza (atezolizumab-hyaluronidase-tqjs) is an oncology therapy covered under this policy for specified solid tumor and small cell lung cancer indications. Coverage includes monotherapy and combination regimens, with eligibility for several indications dependent on required tumor biomarker or genomic testing. Prior authorization applies to FDA-approved and qualifying compendial uses, subject to the diagnosis-specific criteria, documentation requirements, and exclusions described in the policy.

    Clinical Abbreviations and Terms

    High PD-L1 expression
    Tumor-cell expressionPD-L1 expression of at least 50% of tumor cells
    Immune-cell expressionPD-L1-stained tumor-infiltrating immune cells covering at least 10% of the tumor area
    Clinical settingAs specified for first-line metastatic NSCLC
    NSCLC
    Full termNon-small cell lung cancer
    Treatment settingsAdjuvant, first-line metastatic, and subsequent-treatment settings
    Additional requirementsSpecified biomarker and genomic requirements apply

    Initial Authorization

    Initial therapy authorization

    Initial authorization may be granted for 6 months when the member meets the applicable disease-specific criteria.

    Eligible initial-treatment indication: The requested therapy meets the applicable criteria for qualifying NSCLC, SCLC, HCC, melanoma, alveolar soft part sarcoma, mesothelioma, or cervical cancer, including required combination agents and biomarker or molecular findings where specified.6-month authorization

    All applicable exclusions and documentation requirements also apply.

    Initial mesothelioma authorization

    Authorization of 6 months may be granted.

    Mesothelioma subsequent treatment: The member has subsequent-treatment peritoneal, pericardial, or tunica vaginalis testis mesothelioma.6 months

    Maintenance and Reauthorization

    Maintenance and continuation therapy

    Continuation or maintenance use is covered when it is part of an approved disease-specific regimen.

    Continuation or maintenance pathways: Tecentriq Hybreza is used as continued maintenance monotherapy or with bevacizumab for qualifying NSCLC; following etoposide and carboplatin for extensive-stage SCLC as monotherapy or with lurbinectedin; as monotherapy maintenance for qualifying small cell neuroendocrine carcinoma of the cervix; or with bevacizumab maintenance for qualifying cervical carcinoma.

    Each pathway remains subject to the underlying disease and regimen criteria.

    Continued adjuvant HCC, NSCLC, colon cancer, and small bowel adenocarcinoma therapy

    Authorization of 6 months may be granted, up to 12 months total, for continued adjuvant treatment when the member has not experienced disease recurrence or unacceptable toxicity.

    Adjuvant continuation: The member is receiving continued adjuvant therapy for hepatocellular carcinoma, non-small cell lung cancer, colon cancer, or the covered small bowel adenocarcinoma indication.

    Dose and Frequency Limits

    Tecentriq Hybreza maximum subcutaneous dosing regimen
    DrugTecentriq Hybreza (atezolizumab-hyaluronidase-tqjs)
    RouteSubcutaneous
    Maximum regimen1875/30,000 mg-units every 3 weeks

    Administration Route

    Billing Rule

    Administer the maximum regimen in the office

    The listed maximum dosing regimen is administered by the subcutaneous route in the office setting.

    • Route: subcutaneous
    • Setting: office
    • Maximum regimen: 1875/30,000 mg-units every 3 weeks
    Policy Summary
    PayerBlueCross BlueShield of Tennessee
    PolicyAtezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza) Coverage Criteria
    Policy CodePolicy ID_CHS_66652026_1026
    Change TypeNo material change
    Effective DateDecember 31, 2026
    Next Review DateN/A
    Key ActionPrior authorization is required before review of Tecentriq Hybreza coverage.
    SourceLink
    On This Page
    Covered Indications and ExclusionsClinical Thresholds and Biomarker ValuesAuthorization, Documentation, and Denial RisksTherapy and Policy ContextClinical Abbreviations and TermsInitial AuthorizationMaintenance and ReauthorizationDose and Frequency LimitsAdministration Route
    Pediatric ASPS minimum age
    Minimum age12 years of age or older
    PopulationPediatric patients with unresectable or metastatic alveolar soft part sarcoma
    TreatmentTecentriq Hybreza monotherapy
    Pediatric ASPS minimum weight
    Minimum weight40 kg or greater
    PopulationPediatric patients with unresectable or metastatic alveolar soft part sarcoma
    TreatmentTecentriq Hybreza monotherapy
    Ultra-hypermutated tumor mutational burden
    ThresholdGreater than 50 mutations per megabase
    AbbreviationTMB >50 mut/Mb
    Associated phenotypePOLE/POLD1 mutation with an ultra-hypermutated phenotype
    Tumor mutational burden threshold for specified indications
    Tumor mutational burden threshold>50 mut/Mb
    Specified biomarker statusdMMR/MSI-H or POLE/POLD1 mutation with ultra-hypermutated phenotype
    Specified indicationsColon cancer and small bowel adenocarcinoma
    Documentation Required

    Tennessee Off-Label Coverage Mandate

    For an off-label indication, document that the use is recognized in a statutorily recognized standard reference compendium or in published peer-reviewed medical literature, consistent with Tennessee Code Annotated Section 56-7-2352.

    • Include the applicable compendium or peer-reviewed literature support with the request.
    Documentation Required

    PD-L1 Test Results

    Submit tumor PD-L1 expression test results when applicable to the requested indication, including documentation of PD-L1-positive disease when required by the coverage criteria.

    • Attach the laboratory or pathology report identifying the PD-L1 result.
    Documentation Required

    BRAF V600 Test Results

    Submit test results confirming that the tumor is positive for the BRAF V600 mutation when applicable.

    • Attach the molecular or laboratory report documenting BRAF V600 positivity.
    Documentation Required

    Molecular Testing Results

    Submit molecular testing results when applicable, including documentation of EGFR exon 19 deletion and L858R mutation status and ALK, RET, or ROS1 gene-fusion status.

    • If testing is not feasible because of insufficient tissue, document that limitation.
    Documentation Required

    MSI, Mismatch Repair, and TMB Documentation

    Submit documentation of microsatellite instability, mismatch-repair status, and tumor mutational burden when applicable.

    • Document MSI-H, dMMR, or a POLE/POLD1 mutation with an ultra-hypermutated phenotype and TMB greater than 50 mutations per megabase when required.
    Documentation Required

    Required Tumor Biomarker Documentation

    Include all required tumor biomarker documentation supporting the requested diagnosis and regimen. Missing or incomplete biomarker evidence can prevent the plan from confirming eligibility.

    • Provide the applicable pathology, laboratory, and molecular reports rather than relying only on a clinical narrative.

    Unsupported block type: documentation

    Documentation Required

    Regimen and Safety Support

    Support the requested regimen, dose, route, contraindications, precautions, warnings, and monitoring plan with a standard reference compendium.

    • Acceptable references include NCCN Guidelines, DrugDex Evaluations of Micromedex Solutions, and the American Hospital Formulary Service Drug Information.
    Denial Risk

    Denial Risk: Prior PD-1/PD-L1 Progression

    Coverage will not be provided when the member has experienced disease progression while receiving PD-1 or PD-L1 inhibitor therapy.

    • Review prior immunotherapy history and document that the requested treatment is not being initiated after progression on PD-1 or PD-L1 inhibitor therapy.
    Documentation Required

    NSCLC Molecular Eligibility

    For NSCLC, document the required molecular eligibility: no EGFR exon 19 deletion or L858R mutation and no ALK, RET, or ROS1 gene fusion, unless testing is not feasible because of insufficient tissue.

    • Provide the molecular report or documentation explaining why adequate tissue was unavailable.
    Denial Risk

    Denial Risk: Missing Testing Documentation

    Failure to submit required biomarker or molecular testing documentation may prevent authorization, even when the clinical indication otherwise appears eligible.

    • Verify that PD-L1, BRAF V600, EGFR, ALK, RET, ROS1, MSI, mismatch-repair, and TMB documentation is included when applicable.
    Denial Risk

    Denial Risk: Progression, Recurrence, or Toxicity

    Reauthorization may be denied when the member has disease progression, disease recurrence, or unacceptable toxicity during the current therapy, depending on the indication.

    • Submit current response or disease-status documentation and a safety assessment with each reauthorization request.
    Denial Risk

    Denial Risk: Diagnosis-Specific Criteria

    Authorization may be denied when the diagnosis-specific coverage criteria are not met, including required disease stage, line of therapy, biomarker status, combination regimen, or maintenance-treatment requirements.

    • Match the requested regimen to the applicable diagnosis-specific criterion.
    • Document required companion agents and treatment setting.
    Billing Rule

    Quantity or Dosing Limit

    Do not request quantities or dosing that exceed the policy limit. For Tecentriq Hybreza, the listed maximum regimen is subcutaneous 1,875 mg/30,000 units every 3 weeks for the specified covered diagnoses.

    • Verify the diagnosis-specific maximum dosing regimen before submission.
    • Requests exceeding the quantity, dose, route, or frequency limit may be denied.
    ES-SCLC
    Full termExtensive-stage small cell lung cancer
    Initial regimenCombination with etoposide and carboplatin
    Maintenance optionsSingle-agent therapy or combination with lurbinectedin
    ASPS
    Full termAlveolar soft part sarcoma
    Disease settingUnresectable or metastatic disease
    Eligible pediatric populationPatients 12 years of age or older who weigh 40 kg or greater
    dMMR/MSI-H or POLE/POLD1 ultra-hypermutated phenotype
    Mismatch-repair statusDeficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) tumor status
    Alternative molecular findingPOLE/POLD1 mutation
    Ultra-hypermutated definitionTumor mutational burden greater than 50 mutations per megabase (TMB >50 mut/Mb)

    Combination with bevacizumab is required.

    Initial cervical cancer authorization

    Authorization of 6 months may be granted when either criterion is met.

    Cervical cancer treatment: The member has persistent, recurrent, or metastatic small cell neuroendocrine carcinoma treated with etoposide plus cisplatin or carboplatin; or recurrent/metastatic adenocarcinoma, adenosquamous, or squamous cell carcinoma treated with bevacizumab, paclitaxel, and cisplatin or carboplatin.6 months

    The maintenance uses described in the policy are permitted.

    Initial colon cancer authorization

    Authorization of 6 months may be granted when all criteria are met.

    Colon cancer: The member has stage III colon cancer receiving adjuvant treatment with dMMR/MSI-H or a POLE/POLD1 mutation with an ultra-hypermutated phenotype.TMB >50 mut/Mb

    Use with FOLFOX or CAPEOX followed by single-agent maintenance.

    Initial thymic carcinoma authorization

    Authorization of 6 months may be granted.

    Thymic carcinoma: The member is receiving first-line or postoperative systemic therapy for thymic carcinoma.6 months

    Use with carboplatin and paclitaxel followed by single-agent maintenance.

    Initial chronic lymphocytic leukemia authorization

    Authorization of 6 months may be granted.

    CLL with Richter's transformation: The member has chronic lymphocytic leukemia with Richter's transformation.6 months

    Use with venetoclax and obinutuzumab.

    Initial small bowel adenocarcinoma authorization

    Authorization of 6 months may be granted when the biomarker and treatment-setting criteria are met.

    Small bowel adenocarcinoma: The member has dMMR/MSI-H or POLE/POLD1 ultra-hypermutated small bowel adenocarcinoma in an adjuvant, neoadjuvant, locally unresectable, medically inoperable, advanced, or metastatic setting.TMB >50 mut/Mb

    Adjuvant use is with FOLFOX or CAPEOX followed by single-agent maintenance; neoadjuvant and advanced/metastatic use are single-agent uses.

    Up to 12 months total

    No disease recurrence or unacceptable toxicity.

    Continued thymic carcinoma therapy

    Authorization of 6 months may be granted, up to 24 months total, for continued treatment when the member has not experienced disease progression or unacceptable toxicity.

    Thymic carcinoma continuation: The member is receiving continued treatment for thymic carcinoma.Up to 24 months total

    No disease progression or unacceptable toxicity.

    Continued treatment for all other covered indications

    Authorization of 6 months may be granted for continued treatment of an indication listed in the coverage criteria.

    Other covered indication continuation: The indication is listed in the coverage criteria and the member remains on the current regimen.6-month authorization period

    No evidence of unacceptable toxicity or disease progression while on the current regimen.